Alterity Therapeutics Ltd ADR (NASDAQ: ATHE)’s stock price has gone rise by 13.48 in comparison to its previous close of 4.23, however, the company has experienced a 39.53% increase in its stock price over the last five trading days. globenewswire.com reported 2025-05-07 that MELBOURNE, Australia and SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations related to Alterity’s clinical programs in Multiple System Atrophy (MSA) will be featured at the 2025 International MSA Congress taking place May 9 – 11, 2025 in Boston, MA, USA. The Congress is presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building hope for people affected by MSA through support services, educational resources, research funding, and community engagement.
Is It Worth Investing in Alterity Therapeutics Ltd ADR (NASDAQ: ATHE) Right Now?
Company’s 36-month beta value is 0.72.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ATHE is 14.50M, and currently, short sellers hold a 0.35% ratio of that floaft. The average trading volume of ATHE on May 12, 2025 was 46.47K shares.
ATHE’s Market Performance
The stock of Alterity Therapeutics Ltd ADR (ATHE) has seen a 39.53% increase in the past week, with a 74.23% rise in the past month, and a 12.94% gain in the past quarter. The volatility ratio for the week is 17.44%, and the volatility levels for the past 30 days are at 8.26% for ATHE. The simple moving average for the past 20 days is 31.91% for ATHE’s stock, with a 98.30% simple moving average for the past 200 days.
Analysts’ Opinion of ATHE
Maxim Group, on the other hand, stated in their research note that they expect to see ATHE reach a price target of $8. The rating they have provided for ATHE stocks is “Buy” according to the report published on December 12th, 2024.
ATHE Trading at 35.45% from the 50-Day Moving Average
After a stumble in the market that brought ATHE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.23% of loss for the given period.
Volatility was left at 8.26%, however, over the last 30 days, the volatility rate increased by 17.44%, as shares surge +68.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.03% upper at present.
During the last 5 trading sessions, ATHE rose by +39.53%, which changed the moving average for the period of 200-days by +124.82% in comparison to the 20-day moving average, which settled at $3.64. In addition, Alterity Therapeutics Ltd ADR saw 45.02% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ATHE
Current profitability levels for the company are sitting at:
- -6.06 for the present operating margin
- 0.96 for the gross margin
The net margin for Alterity Therapeutics Ltd ADR stands at -5.31. The total capital return value is set at -2.89. Equity return is now at value -154.88, with -120.38 for asset returns.
Based on Alterity Therapeutics Ltd ADR (ATHE), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -155.63.
Currently, EBITDA for the company is -19.57 million with net debt to EBITDA at 0.2. When we switch over and look at the enterprise to sales, we see a ratio of 28.22. The receivables turnover for the company is 0.66for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.84.
Conclusion
In a nutshell, Alterity Therapeutics Ltd ADR (ATHE) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
